• NAYZILAM will be available in retail pharmacies on December 2, 2019
• Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients*

• The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints¹
• UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020

UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

UCB's Denelle Waynick, VP, Legal Affairs (U.S.), U.S. General Counsel and Global Head, Enterprise Risk Management, leads by example by being true to herself to encourage others to do so too. Read more from Denelle on why by being authentic to yourself, you become stronger as an individual, leader, and employee. Read the full article on LinkedIn.